Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background It is recommended that lovastatin be avoided in patients with unexplained elevation in transaminase levels. However, there are no studies that evaluated the risk of lovastatin hepatotoxicity in subjects with elevated liver enzymes. Our study tested the hypothesis that patients with elevated liver enzymes are not at higher risk for hepatotoxicity from lovastatin.Methods Our study consisted of the following three cohorts of patients seen between December 1987 and December 1998: cohort 1: 135 patients with elevated baseline enzymes (aspartate transaminase [AST] >40 IU/L or alanine transaminase [ALT] >35 IU/L) who received lovastatin; cohort 2: 620 patients without elevated liver enzymes who received lovastatin; and cohort 3: 2644 patients with elevated liver enzymes but not prescribed lovastatin. Elevations in liver biochemistries over a 12-month period after lovastatin was prescribed were categorized into mild-moderate or severe elevations and into "Hy's Rule" based on published criteria.Results The incidence of mild-moderate elevations and severe elevations in liver biochemistries in cohort 1 were 6.6% and 0%, respectively. Compared with cohort 2, individuals in cohort 1 had higher incidence of mild-moderate elevations (6.6% versus 3%; P = 0.03) but not severe elevations (0% versus 0.3%; P = 0.9). Compared with cohort 3, patients in cohort 1 had similar mild-moderate elevations (6.6% versus 11%; P = 0.2) but lower severe elevations (0% versus 5.5%; P < 0.01). No one in cohorts 1 or 2 developed elevations meeting Hy's Rule, whereas 3.5% of the patients in cohort 3 exhibited such elevations (P < 0.05 versus cohort 1 or cohort 2).Conclusions Significant hepatotoxicity from lovastatin was very infrequent in this study, and individuals with elevated baseline liver enzyme levels did not have higher frequency of lovastatin hepatotoxicity than those with normal liver enzyme levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The suggested effect on Alzheimer's disease was recently reviewed in a Cochrane analysis reporting no conclusive effect from statins [230].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [230]
In the citing paper
“Patients with mild ALT elevation due to steatosis have been studied during statin treatment and there is no indication that statins cause any worsening of liver disease. 222-224”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [223]
In the citing paper
“Patients with mild ALT elevation due to steatosis have been studied during statin treatment and there is no indication that statins cause any worsening of liver disease.222e224”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [223]
Citations
Cites
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Arky, R. A. (1994) · Cited by 2,632
The National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 710
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver
Maddrey, W. C. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70192-2 · Cited by 646
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
Self-citationLipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox
Ko, D. T., Mamdani, M., & Alter, D. A. (2004) · JAMA · doi:10.1001/jama.291.15.1864 · Cited by 412
The Regenstrief Medical Record System: a quarter century experience
McDonald, C. J., Overhage, J. M., Tierney, W. M., Dexter, P. R., Martin, D. K., Suico, J. G., Zafar, A., Schadow, G., Blevins, L., Glazener, T., et al. (1999) · International Journal of Medical Informatics · doi:10.1016/s1386-5056(99)00009-x · Cited by 395
Fatty Infiltration of Liver in Hyperlipidemic Patients
Assy, N., Kaita, K., Mymin, D., Levy, C., Rosser, B., & Minuk, G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005661516165 · Cited by 360
Chalasani, N., Deeg, M. A., & Crabb, D. W. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30159.x · Cited by 343
Self-citation
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citation
Metadata
- Authors
- Vuppalanchi, R., Chalasani, N., & Teal, E.
- Affiliations
- Indiana University Indianapolis (US)
- Regenstrief Institute (US)
- Corresponding author
- Chalasani, Naga
- Venue
- The American Journal of the Medical Sciences
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 329
- Issue
- 2
- Pages
- 62-65
- ISSN
- 0002-9629 (ISSN-L)
- OpenAlex
- W2073776492
- Cited by
- 133
- References
- 30
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 9 · 2018: 4 · 2017: 3 · 2016: 9 · 2015: 10 · 2014: 12 · 2013: 15 · 2012: 10
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The American Journal of the Medical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- lovastatin, drug-induced liver injury, elevated liver enzymes, aspartate aminotransferase, alanine aminotransferase, statins, drug safety, adverse drug reactions
- MeSH terms
- Adult, Aged, Female, Humans, Liver, Liver Function Tests, Lovastatin, Male, Middle Aged, Cohort Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes. https://app.cochat.ai/papers/10.1097/00000441-200502000-00002
- The paper
- Vuppalanchi, R., Chalasani, N., & Teal, E. (2005). Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes. The American Journal of the Medical Sciences. https://doi.org/10.1097/00000441-200502000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.